NIS蛋白在三阴性乳腺癌中的表达

NIS Expression in Triple-Negative Breast Cancers

目的研究钠碘同向转运体(NIS)在三阴性乳腺癌中的表达,并探讨其在术后131I治疗效果预测方面的临床应用价值。方法随机挑选三阴性乳腺癌(TNBC)30例作为实验组,同时随机挑选30例非三阴性乳腺癌(non-TNBC)和上述三阴性乳腺癌的癌旁组织30例作为对照组,应用免疫组化SP法检测NIS蛋白在非三阴性乳腺癌、三阴性乳腺癌及其癌旁组织中的表达,并比较表达差异。结果 NIS蛋白在non-TNBC组、TNBC组及癌旁组织的阳性表达率分别为73.3%(22/30)、66.7%(20/30)、6.7%(2/30),NIS在TNBC组和non-TNBC组表达差异无统计学意义(P>0.05),TNBC组和癌旁组织组比较差异显著(P<0.05),non-TNBC组和癌旁组织组比较差异显著(P<0.05)。结论 NIS在三阴性乳腺癌中强表达,提示NIS介导的131I治疗三阴性乳腺癌有广阔的临床应用前景。

Objective To study the clinical value of Na＋/I-symporter（NIS） expression on triple-negative breast cancer and prediction of 131 I therapeutic effect. Methods 30 samples of triple-negative breast cancer（triple-negative breast cancer,TNBC）were randomly selected as the experimental group,and 30 samples of non-triple negative breast cancer（non-triple-negative breast cancer,non-TNBC）and adjacent tissue of above 30 samples of the triple negative breast cancer,randomly selected as a comparable group,NIS expression was detected by SP immunohistochemical technique and compared with their the differences. Results In triple-negative breast cancer,its adjacent tissue and non-triple negative breast cancer,the positive rates of NIS expression were 66.7 %（20/30）,73.3 %（22/30） and 6.7%（2/30） respectively,NIS in Non-triple negative breast cancer group and triple-negative breast cancer group showed no statistic differences（P〉0.05）,triple-negative breast cancer group and its adjacent tissue group showed differences significantly（P〈0.05）,non-three-negative breast cancer group and adjacent tissue of the above triple negative breast cancer tissue group showed differences significantly（P〈0.05）. Conclusion NIS is strongly expressed in a significant proportion of triple-negative breast cancer cells,suggesting a potential role for NIS-directed 131I-radioablative strategies in this patient population.